The company hiked its full-year adjusted earnings forecast to between $5.40 and $5.50 a share, up from the previous range of between $5.10 to $5.20. Lilly's estimates reflect its decision not to increase U.S. list prices for the rest of the year, CEO Dave Ricks said in a statement.
"We're sensitive to the debate going on," Lilly CEO Dave Ricks told CNBC's "Squawk Box" on Tuesday. "We know consumers want us to restrain, and we really need to see what comes out of this blueprint, which is potentially a sweeping set of reforms that Secretary Azar and the administration's rolled o